Emgality vs Gabapentin
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Emgality | US Gabapentin | |
|---|---|---|
| Generic name | galcanezumab | gabapentin |
| Drug class | CGRP Antagonist (Biologic) | Anticonvulsant / Nerve Pain Agent |
| Treats | Migraine prevention, cluster headache | Nerve pain, seizures |
| Category | Neurology | Neurology |
| Manufacturer | Eli Lilly | Various (generic) |
| Year approved | 2018 | 1993 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $110M | $1M |
| Common side effects | Injection site reactions, Constipation, Itching, Allergic reactions | Drowsiness, Dizziness, Swelling, Coordination problems |
Gabapentin
Frequently asked questions
Is Emgality or Gabapentin better?
Neither is universally "better." Emgality (galcanezumab) and Gabapentin (gabapentin) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Emgality and Gabapentin?
Emgality is a CGRP Antagonist (Biologic) made by Eli Lilly, while Gabapentin is a Anticonvulsant / Nerve Pain Agent made by Various (generic). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Emgality has the larger estimated TV advertising budget of the two.